Shares of biopharmaceutical research firm BeiGene Ltd. (Nasdaq: BGNE) shot up almost 10 percent Wednesday on news of a new cancer treatment and an optimistic report by influential investment firm Maxim Group, which raised its price target for the commercial-stage research group by 20 percent, from $120 to $144 per share.
http://www.capitalwatch.com/article-1710-1.html
BeiGene Shares Rise on Analyst Estimates and News of a Cancer Cure Trial